CRISPR Therapeutics AG

CRSP Nasdaq CIK: 0001674416

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation Switzerland
Country Switzerland
Business Address BAARERSTRASSE 14, ZUG, ,
Mailing Address BAARERSTRASSE 14, ZUG, ,
Phone 6173154600
Fiscal Year End 1231
EIN 473173478

Financial Overview

FY2025

-$153.61M
Net Income
$2.27B
Total Assets
$343.43M
Total Liabilities
$1.93B
Stockholders' Equity
$389.48M
Cash & Equivalents
$-1.94
EPS

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report February 12, 2026 View on SEC
8-K Current report of material events February 12, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 5, 2026 View on SEC
4 Insider stock transaction report January 27, 2026 View on SEC
4 Insider stock transaction report January 26, 2026 View on SEC
4 Insider stock transaction report January 22, 2026 View on SEC
8-K Current report of material events January 12, 2026 View on SEC
4 Insider stock transaction report January 8, 2026 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
4 Insider stock transaction report December 22, 2025 View on SEC

Annual Reports

10-K February 12, 2026
  • Successful launch of CASGEVY (exagamglogene autotemcel) for sickle cell disease and transfusion-dependent beta thalassemia, securing landmark regulatory approvals in the U.S., Europe, and UK.
  • Reported total revenue of $350 million for fiscal year 2025, a substantial increase from $120 million in 2024, driven by collaboration revenue and initial CASGEVY sales.
View Analysis

Insider Trading

STRONG SELL 2 insiders 10 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.